San Diego-centered Viking Therapeutics marked itself as a significant competitor during the weight loss drug industry in February soon after revealing promising data from the mid-phase trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when offered for a weekly injection As well as in March the com